Brief: Landos Biopharma Announces First Subject Dosed In A Phase 1 Study Of Labp-104 For Systemic Lupus Erythematosus
28/10/2021 13:20
Oct 28 (Reuters) - Landos Biopharma Inc LABP.O :
* LANDOS BIOPHARMA ANNOUNCES FIRST SUBJECT DOSED IN A PHASE
1
STUDY OF LABP-104 FOR SYSTEMIC LUPUS ERYTHEMATOSUS
* LANDOS BIOPHARMA INC - TOPLINE RESULTS ARE EXPECTED IN
FIRST
HALF OF 2022
Source text for Eikon: ID:nGNX5Lhv29
Further company coverage: LABP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Landos Biopharma
See all newsLandos Biopharma Inc expected to post a loss of 100 cents a share - Earnings Preview
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Super Micro, Micron Technology, Navios Maritime
U.S. STOCKS ON THE MOVE-Landos Biopharma, Foot Locker, US energy sector
Brief: AbbVie To Acquire Landos Biopharma